XNCR
Xencor, Inc.
NASDAQ · USHealthcareBiotechnology
$18.81+7.67%
Price as of Jul 20, 2026
XNCR growth
Xencor, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -29.2%
- EBITDA
- +13.0%
- EBIT
- -35.4%
- EPS
- +27.8%
- Free cash flow
- -7.9%
- Operating cash flow
- -12.9%
Forward estimates
- Revenue
- +32.5%
- EBITDA
- +89.5%
- EPS
- -28.1%
Three-year CAGR
- Revenue
- -8.6%
- EBITDA
- +74.8%
- EBIT
- +0.5%
- Net income
- +60.5%
- EPS
- +65.4%
- Free cash flow
- +33.6%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.